Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer.

Trial Profile

Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Bevacizumab; Gimeracil/oteracil/tegafur; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 28 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 27 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Planned end date changed from Jun 2010 to Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top